Global leadership in design and manufacturing
targets better dialysis patient outcomes for U.S. market
Miami, Florida – February 6, 2014: Nipro Medical Corporation, a subsidiary for North & South America Sales and Marketing of Nipro Corporation in Japan, a world leader in dialyzer design and manufacturing, today announced the introduction of the ELISIO™ Polynephron™ Single Use, High-Flux, Hollow-Fiber Dialyzer. The ELISIO™ features a state-of-the-art Polynephron™ membrane similar in function to that of a human kidney delivering outstanding biocompatibility, hemocompatibility, and solute-removal performance, resulting in superior clearances for better patient outcomes. The ELISIO™ Polynephron Dialyzer has received 510(K) clearance from the U.S. Food and Drug Administration (FDA). The product is designed for the renal market, targeting those involved in care and procedures for kidney disease and dialysis.
“Nipro dialyzers have been the preferred product for dialysis around the globe for the past 30 years,” said Joe Dawson, Senior Vice President, Nipro North America. “The introduction of the ELISIO™ dialyzer builds on our strategy of becoming a complete and cost-effective dialysis solutions leader, offering blood tubing lines, fistulas needles, and now dialyzers to our dialysis market partners in the U.S. market. ELISIO™ is designed to deliver an elevated benefits platform to the market, especially in clearance performance of small to middle molecules, and it delivers on these objectives.”
The sophisticated ELISIO™ membrane provides thousands of fibers where each fiber acts like a nephron – the functional unit of the kidney, responsible for the actual purification and filtration of the blood. A 3D chemical structure affords an ideal mixture of hydrophilic and hydrophobic domains, while reducing membrane fouling and maximizing membrane performance.
The ELISIO™ dialyzer’s advanced pore-spinning technology creates more homogenous pore sizes to optimize sieving properties. In addition, the unique ripple structure in ELISIO’s fiber creates less dialysate channeling – promoting better diffusive transport while enhancing small molecule clearances, and reducing the risk of fiber leakage.
“Both in-vitro and in-vivo testing have demonstrated the superior clearance performance of the ELISIO™ dialyzer for both small and middle molecules,” Dawson said. “In addition, clinicians reported excellent performance with regard to myglobin and B2 microglobulin, and excellent biocompatibility on WBC and C5a.”
The ELISIO™ dialyzer’s inner design offers a very smooth polyurethane cut surface that helps minimize the risk of blood cell damage. An improved header shape reduces channeling at the blood side, and the redesigned permanent caps eliminate the possibility of unexpected removal or reuse.
“Innovative features that deliver better dialysis patient outcomes are what Nipro has been delivering for more than 30 years,” Dawson said. “The ELISIO™ dialyzer builds on this performance promise.”
The ELISIO™ Polynephron™ Single Use, High-Flux, Hollow-Fiber Dialyzer is available in sizes from 90H to 250H. For complete performance parameters and product specifications, or for more information, visit niproadmin.wpengine.com or call
About Nipro Medical: Nipro Corporation is a world-leading manufacturer of Renal and Medical-Surgical products. The Company is committed to educating customers and delivering innovative, high quality and value-added solutions to improve patient care. Nipro Medical Corporation is a wholly owned subsidiary of Nipro Corporation, headquartered in Osaka, Japan.
- 02 Nov 2017Nipro Medical Corporation Launches the Cellentia®-H Cellulose Triacetate (CTA), Single-Use Dialyzer at the 2017 ASN Kidney Week Conference
- 22 Apr 2016NIPRO MEDICAL CORPORATION LAUNCHES THE SAFETOUCH™ SAFETY NEEDLE
- 18 Feb 2016NIPRO MEDICAL CORPORATION LAUNCHES THE AQUALINER II SECOND GENERATION 0.035” HYDROPHILIC, SUPER-ELASTIC NITINOL GUIDEWIRE IN THE UNITED STATES
- 09 Jul 2015NIPRO MEDICAL CORPORATION INTRODUCES NIPRO VSMART™ SYRINGES AT THE 2015 AMERICAN VETERINARY MEDICAL ASSOCIATION CONVENTION